1. A pharmaceutical composition comprised of a solution comprising synthetic peptide in admixture with a polyol; wherein the synthetic peptide is an HIV fusion inhibitor; wherein the synthetic peptide is in a final concentration in the pharmaceutical composition of not less than 70 mg/ml and not more than 500 mg/ml; and wherein the polyol is in a final concentration of no less than 5 weight % and no more than 75 weight % of the pharmaceutical composition.

2. The pharmaceutical composition according to claim 1, wherein the synthetic peptide is in a final concentration in the pharmaceutical composition of not less than 100 mg/ml and not more than 250 mg/ml.

3. The pharmaceutical composition according to claim 1, wherein the polyol is in a final concentration of no less than 10 weight % and no more than 50 weight % of the pharmaceutical composition.

4. The pharmaceutical composition according to claim 1, wherein the polyol comprises polyethylene glycol.

5. The pharmaceutical composition according to claim 1, further comprising a pharmaceutically acceptable carrier additional to the polyol.

6. A method of treating HIV infection (preferably, HIV-1 infection) comprising administering to an HIV-infected individual a pharmaceutical composition according to claim 1.

7. A pharmaceutical composition comprised of a solution comprising synthetic peptide in admixture with a polyol; wherein the synthetic peptide is an HIV fusion inhibitor; wherein the synthetic peptide is in a final concentration in the pharmaceutical composition of not less than 100 mg/ml and not more than 250 mg/ml; and wherein the polyol is in a final concentration of no less than 10 weight % and no more than 50 weight % of the pharmaceutical composition.

8. The pharmaceutical composition according to claim 7, wherein the polyol comprises polyethylene glycol.

9. The pharmaceutical composition according to claim 7, further comprising a pharmaceutically acceptable carrier additional to the polyol.

10. A method of treating HIV infection (preferably, HIV-1 infection) comprising administering to an HIV-infected individual a pharmaceutical composition according to claim 7.

11. A synthetic peptide-containing pharmaceutical composition as a unit dose, wherein the pharmaceutical composition comprises an aqueous formulation comprising: (a) a polyol present as a pharmaceutically acceptable carrier in an amount not less than 5 weight % and not more than 75 weight % of the pharmaceutical composition as a unit dose; and (b) synthetic peptide comprising an HIV fusion inhibitor in a final concentration of the pharmaceutical composition of not less than 70 mg/ml and not more than 500 mg/ml.

12. The synthetic peptide-containing pharmaceutical composition according to claim 11, wherein the synthetic peptide is in a final concentration in the pharmaceutical composition of not less than 100 mg/ml and not more than 250 mg/ml.

13. The synthetic peptide-containing pharmaceutical composition according to claim 11, wherein the polyol is in a final concentration of no less than 10 weight % and no more than 50 weight % of the pharmaceutical composition.

14. The synthetic peptide-containing pharmaceutical composition according to claim 11, wherein the polyol comprises polyethylene glycol.

15. The synthetic peptide-containing pharmaceutical composition according to claim 11, further comprising a pharmaceutically acceptable carrier additional to the polyol.

16. A method of treating HIV infection (preferably, HIV-1 infection) comprising administering to an HIV-infected individual a synthetic peptide-containing pharmaceutical composition according to claim 11.

17. A synthetic peptide-containing pharmaceutical composition as a unit dose, wherein the pharmaceutical composition comprises an aqueous formulation comprising: (a) a polyol present as a pharmaceutically acceptable carrier in an amount not less than 10 weight % and not more than 50% of the pharmaceutical composition as a unit dose; and (b) synthetic peptide comprising an HIV fusion inhibitor in a final concentration of the pharmaceutical composition of not less than 100 mg/ml and not more than 250 mg/ml.

18. The synthetic peptide-containing pharmaceutical composition according to claim 17, wherein the polyol comprises polyethylene glycol.

19. The synthetic peptide-containing pharmaceutical composition according to claim 17, further comprising a pharmaceutically acceptable carrier additional to the polyol.

20. A method of treating HIV infection (preferably, HIV-1 infection) comprising administering to an HIV-infected individual a synthetic peptide-containing pharmaceutical composition according to claim 17.